KalVista Insider: 6,250 RSUs Vest; 2,942 Shares Sold to Cover Taxes
Rhea-AI Filing Summary
Audhya Paul K., Chief Medical Officer and director of KalVista Pharmaceuticals, reported equity transactions in the company in late August 2025. On 08/21/2025 the reporting person was issued 6,250 restricted stock units (RSUs) that convert one-for-one into common shares upon settlement, bringing beneficial ownership to 122,783 shares. On 08/22/2025 the reporting person sold 2,942 shares at $13.2228 per share, reducing beneficial ownership to 119,841 shares. The sale was a sell-to-cover transaction to satisfy tax withholding obligations related to the RSU vesting, not a discretionary sale. The RSU award vests in 1/16th increments each quarterly anniversary starting May 21, 2025, subject to continued service.
Positive
- RSU grant settled demonstrating continued executive equity compensation alignment with shareholders
- Substantial remaining insider stake of 119,841 shares after the sell-to-cover
Negative
- Sell-to-cover transaction reduced holdings by 2,942 shares, though it was for tax withholding
- Future dilution possible as additional RSU tranches vest per the 1/16th quarterly schedule
Insights
TL;DR: Routine equity compensation vesting with a tax-related sell-to-cover; not a material change to insider stake.
The Form 4 shows standard compensation mechanics: 6,250 RSUs vested and were settled resulting in increased beneficial ownership before a subsequent sell-to-cover of 2,942 shares at $13.2228 per share to satisfy tax obligations. The net position remains 119,841 shares, indicating continued alignment with shareholder interests. There is no indication of discretionary trading or large-scale divestiture that would signal a change in insider outlook. Impact on valuation or control is immaterial given the size of the transactions reported.
TL;DR: Disclosure reflects standard insider compensation and required tax withholding; governance procedures appear followed.
The filing discloses vesting terms and the sell-to-cover rationale, which aligns with proper disclosure practices. Vesting schedule is explicit: 1/16th quarterly from May 21, 2025, which clarifies future potential dilution from additional RSU settlements. The Form 4 was signed by an attorney-in-fact, indicating procedural execution of the filing. No governance red flags or unexplained transactions are present in this disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,942 | $13.2228 | $39K |
| Exercise | Restricted Stock Unit | 6,250 | $0.00 | -- |
| Exercise | Common Stock | 6,250 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.
